The clinical manifestations of acute infection with Coxsackie B virus are varied and include epidemic pleurodynia, myopericarditis, meningoencephalitis, and pancreatitis. In most cases the infection is self limiting and does not result in chronic tissue damage, but it has also been associated with the development of polymyositis,l cardiomyopathy,' and diabetes mellitus.3 Arthritis is not widely recognised as either an acute or a chronic manifestation of infection with Coxsackie virus, and only one series, of six patients, has been reported previously.4 We report on three further patients, who developed febrile seronegative arthritis in association with clinical and serological evidence of Coxsackie infection; one subsequently developed a progressive erosive polyarthritis.
Case histories
Case I-A 31 year old man with a history of low backache developed pleurisy, myopericarditis, and polyarthritis affecting the hips, shoulders, wrists, distal interphalangeal joints, knees, ankles, and left sternoclavicular joint. He also developed severe low backache and spinal stiffness. Erythrocyte sedimentation rate was 97 mm in the first hour, haemoglobin concentration 11-7 g/dl, and white cell count 11-9x 109/1. Viral antibody titres were consistent with recent infection with Coxsackie B2, with a late rise in antibody against the cross reacting serotype Coxsackie B4 ( Arsenic was widely used in the past to treat neurological disease, especially epilepsy and neurosyphilis, and psoriasis. Its use was limited by frequent toxic side effects, and most patients developed hyperkeratotic dermatitis, which occasionally progressed to squamous carcinoma. Other tumours occur after prolonged exposure, and tumours of the nasopharynx and bronchus and haemangiosarcoma of the liver are well recognised. More recently arsenic has been implicated in the development of non-cirrhotic portal hypertension.1 2 In the 1940s and 1950s a trial of arsenical drugs in multiple sclerosis was conducted in Birmingham.3 We report on a patient with possible long term sequelae of this treatment.
Case report
In 1957 a 32 year old car delivery man presented with recurrent transient neurological disturbances including paraplegia, blindness, cerebellar ataxia, and monoparesis. Multiple sclerosis was diagnosed. He was entered into the arsenic trial and received alternate-day injections of neoarsphenamine (sodium 3-amino-4,4-dihydroxy-3-sulphinomethylaminoarsenobenzene) for three months and Fowler's Solution (arsenic trioxide 1%) by mouth, which he continued to take daily for four years until his skin became "grey and scaly." In 1967 haematuria led to the diagnosis and treatment of a transitional cell tumour of the bladder. Later that year he presented with the first of 32 major gastrointestinal haemorrhages.
In 1969, during a severe haemorrhage not responding to conservative measures, emergency laparotomy was performed. No ulcer was seen, gastric erosions were noted, and the left gastric artery was ligated. Six months later laparotomy for severe haematemesis produced similar findings, and a Polya gastrectomy was performed. Subsequently liver biopsy specimens repeatedly
